Magnesium Carbonate

證據等級: L5

預測適應症: 10 個

Magnesium Carbonate: From Antacid Use to Active Peptic Ulcer Disease

One-Sentence Summary

Magnesium carbonate (MgCO₃) is an alkaline mineral compound historically used as an antacid component in over-the-counter gastrointestinal preparations, though it carries no formally registered therapeutic indication in India. The TxGNN model predicts it may be effective for Active Peptic Ulcer Disease with a confidence score of 99.96%, directly consistent with its established acid-neutralizing chemistry. This direction is currently supported by 0 registered clinical trials and 4 publications (including 3 RCTs), placing it at evidence level L2.

Quick Overview

Item	Content
Original Indication	No formally registered indication (used as antacid excipient/component)
Predicted New Indication	Active Peptic Ulcer Disease
TxGNN Prediction Score	99.96%
Evidence Level	L2
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Magnesium carbonate is an inorganic alkaline salt that reacts directly with hydrochloric acid in the stomach via a well-characterized neutralization reaction: MgCO₃ + 2HCl → MgCl₂ + H₂O + CO₂. This reaction effectively raises intragastric pH to ≥3.5, reducing the corrosive impact of gastric acid on the ulcerated mucosa. The mechanism is straightforward and mechanistically inseparable from the very pathophysiology of acid-peptic ulcer disease — excessive acid secretion eroding an insufficiently protected mucosal barrier.

The pathological link between magnesium carbonate’s mechanism and active peptic ulcer disease is direct and biologically well-founded. Peptic ulcers develop when the balance between aggressive factors (acid, pepsin) and defensive factors (mucus, bicarbonate, prostaglandins) is disrupted. Acid neutralization by an antacid like magnesium carbonate directly addresses the aggressive side of this equation, reducing acid load on exposed ulcer beds and allowing mucosal healing to proceed. Multiple RCTs from the 1980s — when antacids were still first-line therapy — demonstrated healing rates of 50–75% at 3–4 weeks with high-dose antacid regimens, comparable to cimetidine (H2 antagonist) in head-to-head trials.

Currently, detailed mechanism-of-action data from DrugBank is not available for this candidate. However, based on its well-known physicochemical properties, magnesium carbonate belongs to the antacid class (alkaline carbonate salts) alongside calcium carbonate and sodium bicarbonate. Its empirical efficacy in acid-related GI conditions is supported by decades of clinical use in compound antacid formulations such as Caved-S and Novaluzid, both of which contain magnesium salts as active components.

Clinical Trial Evidence

Currently no clinical trials specifically registered for Magnesium Carbonate in Active Peptic Ulcer Disease.

Note: For the broader “Stomach Disease” category (Rank 7 indication), 2 completed Phase 1 trials directly assessed the antacid activity of magnesium-containing preparations using pH-metry (NCT03069963, n=24) and gamma scintigraphy (NCT03065816, n=34), providing indirect pharmacodynamic support.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
7034155	1981	RCT	Scand J Gastroenterol	72-patient 12-week double-blind trial: antacid + anticholinergic vs. cimetidine vs. placebo in active duodenal/prepyloric ulcers; 50% healing at 3 weeks with antacid arm (vs. 67% cimetidine, 17% placebo)
6755656	1982	RCT	Scand J Gastroenterol Suppl	Treatment of active prepyloric and duodenal ulcers comparing antacid/anticholinergic regimen vs. cimetidine vs. placebo; confirms antacid efficacy in active ulcer healing
3003883	1985	RCT	Scand J Gastroenterol	80-patient 4-week RCT: antacid tablets (120 mmol HCl/day neutralizing capacity) in active duodenal ulcer; healing rates 60–67.5% across dietary arms, demonstrating antacid monotherapy efficacy
35720246	2022	Cross-sectional/Lab	Medicine and Pharmacy Reports	Evaluation of acid-neutralizing capacity (ANC) of antacid formulations marketed in Morocco; provides in vitro characterization of antacid class including carbonate-based preparations

India Market Information

Magnesium carbonate (DB09481) currently has no approved drug registrations in India. The drug is not marketed as a standalone therapeutic agent.

Magnesium carbonate may appear as an excipient or minor component in compound antacid formulations, but no standalone CDSCO license has been identified in the dataset.

Safety Considerations

Drug Interactions (197 interactions identified via DDInter):

Key clinically significant interactions to be aware of:

Severity	Interacting Drug	Clinical Relevance
Major	Dolutegravir	Magnesium ions chelate dolutegravir, significantly reducing absorption; must separate dosing by ≥2 hours
Moderate	Alendronic acid / Risedronic acid	Divalent cations markedly reduce bisphosphonate absorption; avoid co-administration
Moderate	Doxycycline	Magnesium chelates tetracycline-class antibiotics; administer separately
Moderate	Azithromycin	Potential reduction in macrolide bioavailability
Moderate	Baloxavir marboxil	Polyvalent cations (Mg²⁺) reduce antiviral absorption; clinically significant
Moderate	Atazanavir	Gastric pH elevation impairs atazanavir absorption (requires acidic environment)
Moderate	Cholecalciferol	Interaction with fat-soluble vitamin metabolism
Moderate	Acetylsalicylic acid	Alkaline pH may alter salicylate absorption and urinary excretion
Moderate	Amphetamine / Benzphetamine	Urinary alkalinization by magnesium reduces amphetamine excretion, increasing CNS effects
Minor	Famotidine / Ranitidine	Additive acid suppression; generally manageable
Minor	Atenolol / Acebutolol	Minor reduction in beta-blocker absorption

General safety note: For detailed warnings and contraindications, please refer to the package insert or prescribing information, as this data was not available in the current evidence pack. Particular attention is warranted in patients with renal impairment (risk of hypermagnesemia with regular use) and patients on drugs with pH-dependent or chelation-sensitive absorption profiles.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link between magnesium carbonate and active peptic ulcer disease is clear and biologically direct — acid neutralization is the classical mechanism for reducing mucosal injury in acid-peptic disease, supported by multiple Phase 2/3-level RCTs demonstrating antacid efficacy comparable to H2 antagonists. However, current evidence comes exclusively from compound antacid formulations (not pure magnesium carbonate), and the modern standard of care has shifted to PPI-based H. pylori eradication regimens, requiring careful positioning of any new antacid-based development.

To proceed, the following is needed:

H. pylori status stratification: Any new trial must screen and stratify patients for H. pylori status; H. pylori-positive patients require concurrent eradication therapy
Monotherapy evidence: Existing RCTs used compound antacid formulations; a Phase 2 trial with pure magnesium carbonate is needed to isolate its individual contribution
Renal safety monitoring plan: Regular assessment of serum magnesium levels, especially in patients with CKD (eGFR <60 mL/min/1.73m²), where hypermagnesemia risk is clinically meaningful
Regulatory pathway clarification: Define whether this would be developed as a prescription drug, OTC antacid, or medical device food under CDSCO guidelines
TFDA prescribing information / package insert (data gap DG001): Needed to complete the safety assessment before advancing to Stage 1 screening
India market entry feasibility: Assess whether a standalone magnesium carbonate antacid formulation has commercial viability given competition from established PPIs, H2 blockers, and combination antacids already on the market
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.